Icterliv 300 Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid used primarily in the treatment of various cholestatic liver diseases. Ursodeoxycholic Acid acts by reducing the cholesterol content of bile and bile stones, promoting bile flow, and protecting hepatocytes against cytotoxicity induced by hydrophobic bile acids. Icterliv 300 is indicated for the management of primary biliary cholangitis, intrahepatic cholestasis of pregnancy, and certain types of gallstone dissolution. Additionally, it may be employed in the treatment of chronic liver diseases characterized by impaired bile secretion. The drug facilitates the improvement of liver function tests and alleviates symptoms such as pruritus and fatigue associated with cholestasis. Icterliv 300 is generally well tolerated, with side effects including mild gastrointestinal disturbances such as diarrhea and nausea. It is contraindicated in patients with complete biliary obstruction and should be used cautiously in individuals with impaired liver function. Dosage and duration of therapy must be individualized based on the clinical condition and response to treatment. Regular monitoring of liver function tests is recommended to assess therapeutic efficacy and detect potential adverse effects. Icterliv 300 Tablet should be administered under medical supervision to ensure optimal outcomes in liver-related disorders.